Poolbeg Pharma Plc POLB
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Poolbeg Pharma Plc shares you hold and we'll calculate your dividend payments:
Sign up for Poolbeg Pharma Plc and we'll email you the dividend information when they declare.
Add Poolbeg Pharma Plc to receive free notifications when they declare their dividends.
Your account is set up to receive Poolbeg Pharma Plc notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Poolbeg Pharma Plc dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0p | — |
| 2007 | 0.0p | 0% |
| 2008 | 0.0p | 0% |
| 2009 | 0.0p | 0% |
| 2010 | 0.0p | 0% |
| 2011 | 0.0p | 0% |
| 2012 | 0.0p | 0% |
| 2013 | 0.0p | 0% |
| 2014 | 0.0p | 0% |
| 2015 | 0.0p | 0% |
| 2016 | 0.0p | 0% |
| 2017 | 0.0p | 0% |
| 2018 | 0.0p | 0% |
| 2019 | 0.0p | 0% |
| 2020 | 0.0p | 0% |
| 2021 | 0.0p | 0% |
| 2022 | 0.0p | 0% |
| 2023 | 0.0p | 0% |
| 2024 | Sign Up Required | |
Poolbeg Pharma Plc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 20 April 2023
- 52 Week Low
- 0.0% on 20 April 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Poolbeg Pharma Plc
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a capital light clinical model. The Company is focused on targeting the medical needs to treat and prevent infectious disease. The Company's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The Company's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The Company is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.
- Sector
- Health Care Equipment & Services
- Country
- United Kingdom
- Share Price
- £0.10 (yesterday's closing price)
- Shares in Issue
- 500 million
- Market Cap
- £52mn
- 0
- Market Indices
- none
